Clinical Trial Update: Investigator Initiated Study to Assess the Safety of Combination of CLS-015 With Anti-CD-19 CAR-T Cells in Patients With Stable/Progressive Large B Cell Lymphoma at Lymphodepletion. [Phase 1]

View source ↗

Summary

Investigator-initiated Phase 1 study to evaluate the safety of combining CLS-015 with anti-CD-19 CAR-T cells in patients with diffuse large B-cell lymphoma; the…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Anti-CD-19 CAR-T cells (CD19-targeted chimeric antigen receptor T cells)
• CLS-015

Snippet

Sponsor: Tel-Aviv Sourasky Medical Center | Conditions: Large B-Cell Lymphoma (LBCL) | Phase 1 | Status: NOT_YET_RECRUITING